Trial Profile
Targeting a Genomic Biomarker for PET Imaging and Staging of Urothelial Cancer: A Preliminary Evaluation
Status:
Active, no longer recruiting
Phase of Trial:
Phase 0
Latest Information Update: 07 Jun 2023
Price :
$35
*
At a glance
- Drugs NLS VPAC1 (Primary)
- Indications Bladder cancer; Urogenital cancer
- Focus Diagnostic use
- 02 Jun 2023 Planned End Date changed from 1 Jan 2023 to 1 Apr 2024.
- 13 Dec 2022 Planned End Date changed from 30 Jan 2022 to 1 Jan 2023.
- 13 Dec 2022 Planned primary completion date changed from 1 Jan 2022 to 1 Jan 2023.